0K16 Stock Overview
A performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Evolus, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.64 |
| 52 Week High | US$17.81 |
| 52 Week Low | US$9.46 |
| Beta | 1.31 |
| 11 Month Change | -23.18% |
| 3 Month Change | -19.98% |
| 1 Year Change | 31.76% |
| 33 Year Change | 140.36% |
| 5 Year Change | -11.28% |
| Change since IPO | -36.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0K16 | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 4.8% | 5.0% | 2.2% |
| 1Y | 31.8% | 2.5% | 8.8% |
Return vs Industry: 0K16 exceeded the UK Pharmaceuticals industry which returned 2.5% over the past year.
Return vs Market: 0K16 exceeded the UK Market which returned 8.8% over the past year.
Price Volatility
| 0K16 volatility | |
|---|---|
| 0K16 Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0K16's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0K16's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 322 | David Moatazedi | www.evolus.com |
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names.
Evolus, Inc. Fundamentals Summary
| 0K16 fundamental statistics | |
|---|---|
| Market cap | US$802.28m |
| Earnings (TTM) | -US$55.46m |
| Revenue (TTM) | US$248.33m |
3.2x
P/S Ratio-14.5x
P/E RatioIs 0K16 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0K16 income statement (TTM) | |
|---|---|
| Revenue | US$248.33m |
| Cost of Revenue | US$74.64m |
| Gross Profit | US$173.69m |
| Other Expenses | US$229.15m |
| Earnings | -US$55.46m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.88 |
| Gross Margin | 69.94% |
| Net Profit Margin | -22.33% |
| Debt/Equity Ratio | 2,057.9% |
How did 0K16 perform over the long term?
See historical performance and comparison